You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils

Adjuvant Chemotherapy Following Complete Resection of Soft Tissue Sarcoma in Adults

Version: 2 ID: 11-2 Oct 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: Education and Information
Sarcoma Disease Site Group

Patient Population

Adult patients with resected soft tissue sarcoma.

Research Question(s)

  1. What are the benefits of anthracycline-based adjuvant chemotherapy in adult patients with completely resected soft tissue sarcomas, in terms of local disease control, systemic recurrence, and overall survival?
  2. When these benefits are assessed in the context of expected toxicities, in what circumstances should adjuvant chemotherapy be recommended?
  3. Are there any advantages in using combination versus single-agent anthracycline-based chemotherapy in the adjuvant setting?
pdf download Full Report (PDF) (907.05 KB)